
Grifols (Nasdaq: GRFS) said it will invest a total of $360 million over 2016-2021, to increase the plasma fractionation capacity …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

